Sebelius Attacks Wellpoint's 39% Rate Hike

by GoozNews ~ 08 Feb 2010 05:36pm

Secretary of Health and Human Services Katherine Sebelius today sent a scathing letter to Anthem Blue Cross of California demanding to know why the Wellpoint Inc. subsidiary is raising that state's individual insurance premiums 39 percent.

"These extraordinary increases are up to 15 times faster than inflation and threaten to make health care unaffordable for hundreds of thousands of Californians, many of whom are already struggling to make ends meet in a difficult economy," she writes. "Your company's strong financial position makes these rate increases even more difficult to understand. As you know, your parent company, WellPoint Incorporated, has seen its profits soar, earning $2.7 billion in the last quarter of 2009 alone."

She could have also pointed out, as Matthew Holt did on the Health Care blog yesterday, that Wellpoint ceo Angela Braly earned nearly $10 million in salary, stock and stock options last year. That ought to get people fired up and ready to go.

What's going on here? Have the Democrats finally found their inner populists now that health care reform is threatened with going down in flames? Last week. House Speaker Nancy Pelosi, a Californian, promised to make her first order of business after returning to Washington (once the runways are cleared of snow) repeal of the 1945 McCarran-Ferguson act, which grants the insurance industry antitrust immunity.

"Anthem Blue Cross has a responsibility to provide a detailed justification for these rate increases to the public," Sebelius wrote. "Additionally, you should make public information on the percent of your individual market premiums that is used for medical care versus the percent that is used for administrative costs. Policy holders in the individual market deserve to know if their premium increases would be invested in better medical care or insurance company overhead costs like salaries, profits, and advertising."

California is already investigating those issues. Is there some reason to think a Federal Trade Commission or Justice Department antitrust investigation would do better?

What situations like this call for isn't tougher antitrust enforcement. It requires systematic regulation and oversight of insurance industry. Rate increases should be reviewed before they are imposed. That is what state regulators do now with electricity and natural gas rates.

However, that can only be done by a powerful state or federal regulator -- sort of like the ones established by the House and Senate health care reform bills.

Californians don't need two, three, many Wellpoints, or jawboning by HHS. What they need is strong regulation of the insurance industry, which can only be delivered through comprehensive health care reform.

The Latest Health Wonk Review . . .

by GoozNews ~ 05 Feb 2010 08:09am

. . . is posted on Joe Paduda's Managed Care Matters website. And while I would tell you to check it out no matter what (since it's a great feature for keeping up with some of the most interesting bloggers following the health care sector today), this week I can't help but point out that Joe featured two of my posts from last week. Thanks Joe! And, for the rest of you, Click Here!

Obama Outlines Healthcare Strategy at Fundraiser

by GoozNews ~ 05 Feb 2010 07:55am

A jobs bill will go first, but then Congress will return to health care legislation, according to the Prescriptions blog on the New York Times website. David Herszenhorn writes:

Congressional Democratic leaders and the White House have been groping for a way forward on the health care legislation. Their main strategy seems to be to work on devising changes to the Senate-passed health care bill that could be attached to a budget measure, which would allow it to be approved by a simple majority. The House could then approve both the Senate bill and the changes and send them in tandem to Mr. Obama for his signature.

Jon Cohn on the New Republic's Treatment blog outlines what he thinks will be in the budget reconciliation compromise:

  • Further reducing the benefits tax, either by further delaying its implementation or raising the threshold at which it begins;
  • Replacing that money by increasing the Medicare tax on unearned income and bigger reductions in subsidies to private insurers that serve Medicare patients;
  • Slightly improving the affordability protections and filling in part of the Medicare drug benefit gap, by further reducing payments to the drug industry;
  • Eliminating special deals like the government's agreement to cover Nebraska's expansion.

 

Half!

by GoozNews ~ 04 Feb 2010 09:19am

Amid all the gloomy numbers in the latest government projections for health care spending, one statistic stands out: Public sector involvement in health care this year will surpass private sector spending for the first time in U.S. history. 

The actual projections show it will only reach 49.3% of $2.57 trillion, but that assumes Congress won't throw more money at physicians at the end of this month when previously legislated cutbacks in Medicare pay are slated to go into effect. Congress can't pass health care reform, but spending more on physicians (mean salary for cardiologists and radiologists in 2009 was over $400,000) has unusual bipartisan support.

What's driving the growing public role is no mystery. With unemployment at 10 percent and underemployment widespread, millions of Americans have lost employer-based coverage and now must rely on public sector programs. Even where people remain employed, their firms can no longer afford skyrocketing premiums and thus are abandoning or cutting back on coverage.

And there's no end in sight to those trends, even with an improving economy. Health care spending, which surged to 17.3% of gross domestic product in 2009 from 16.2 percent in 2008,  the largest single jump in the history of government recordkeeping, is slated to rise to 19.3% in 2019, a year when the public sector will account for 51.9% of the $4.49 trillion health care economy. And that's without paying physicians more.

Here's another way to look at it: In 2019, U.S. government agencies at the state and federal level ALONE will spend 10% of GDP on health. That's a greater share of economic activity than many other highly industrialized nations that insure everyone, yet the U.S. will still have one in six or seven people without any coverage at all at some point during the year.

 

Manufacturing's Sharp Decline

by GoozNews ~ 03 Feb 2010 10:25am

A little off the usual topics of this blog, but this caught my eye and depressed the hell out of me today (from the Wall Street Journal):

During 2009, the nation's capacity to produce motor vehicles and chemicals fell 4.4% and 1.7%, respectively, the largest such declines since at least 1949, according to Federal Reserve estimates. Its capacity to produce semiconductors, by contrast, grew an estimated 10.4%. Overall, U.S. industrial capacity fell by an estimated 1% in 2009, the largest year-to-year decline on record, while goods-producing businesses shed more than 2.3 million jobs.

As a result, economists expect unemployment to remain high for many years as millions of American workers in the hardest-hit sectors struggle to find new jobs. And while some economists see the restructuring as necessary to make U.S. industry leaner and more profitable, others worry that the sheer scope of the cutbacks could doom companies that ought to survive.

"The earthquake that we felt was so big, and the aftershocks so strong, that we could easily destroy perfectly good manufacturers that are crucial in the supply chain," such as auto-parts makers that supply the entire industry, said Diane Swonk, chief economist at Mesirow Financial in Chicago. "That's the great danger, and it's still a risk."

 

 

User Fees Behind FDA Job Growth

by GoozNews ~ 02 Feb 2010 11:21am

The FDA Alliance tirelessly pushes for more money for the Food and Drug Administration, and generally I am supportive. The agency was starved for funds for most of the Bush administration and an adjustment was in order.

But as I pointed out last week, passage of the FDA Amendments Act in 2007 started the rejuvenation process, which is now well underway. Non-user fee employment at the agency grew from 7,116 pre-FDAAA to 9,413 last year. In the budget announced by President Obama yesterday, that total would grow to only 9,689 in 2011, assuming Congress passes the 6 percent or $146 million budgetary increase requested by the president.

In its press release, the 180-member FDA Alliance expressed disapointment in a budget jump that exceeded most other agencies on the discretionary spending list. "The FDA needs a real increase if it is to establish needed new programs and hire new people to carry them out," said Wayne Pines, president of the Alliance.

Why do I think a one-year cooling-off period makes sense?

VBID, Wellness: Market Grows for Consumer Incentives

by GoozNews ~ 01 Feb 2010 08:27am

If health care reform fails, what will the insurance industry do for an encore?

Nearly two decades ago, after insurers successfully campaigned to deep-six President Bill Clinton's health care reform effort, the industry moved tens of millions of Americans with employer-based coverage into health maintenance organizations (HMOs). The shift succeeded in holding down costs for a while. But by the late 1990s, their ham-handed strategy of using HMOs to deny coverage in an irrational manner provoked a patient rights backlash. Faced with the probability of tough new rules regulating their behavior, the insurers backed off and near double-digit health spending growth rates quickly returned.

If their current campaign to defeat reform succeeds, the insurance industry will once again be faced with major decisions about how to curb skyrocketing costs. In recent weeks, there has been renewed attention on two strategies that will probably see much more emphasis in the years ahead. Both would be encouraged by reform, but are not dependent on it. They involve moving people into health plans that 1) use value-based insurance design (VBID), which adjusts co-pays to encourage greater use of and better compliance with high-value health services; and 2) place more emphasis on wellness programs, which reward employees who work to improve their own health (or, in some cases, penalize those who fail).

What's notable about both approaches is that they seek to hold down costs by using economic incentives to change the choices made by millions of patients, who are viewed as health care "consumers." While they claim to borrow a page from the burgeoning field of behavioral economics, which asserts that carefully designed incentive programs can nudge people to do the right thing, the main argument in favor of their eventual success is the expectation that individuals seeking health care will behave like other consumers and gravitate to the least costly alternatives.

What's not expressed, but is equally notable, is that they both absolve health care professionals and the institutions that deliver care from adjusting their own practices, such as the overuse of high technology imaging or invasive procedures, which are the major drivers of skyrocketing health care costs. The architects of VBID and wellness programs assume that it is easier to lower demand that restrict supply. Suppliers, as Elliott Fisher and colleagues at Dartmouth have repeatedly shown, have the uncanny ability to create their own demand and the political acumen to get politicians and patient advocacy groups to scream "rationing" whenever anyone attempts to stand in their way.

But can VBID and greater use of wellness programs actually succeed in bending the cost curve down? And can they do it without triggering a new backlash from patients and the insured public?

The full text is only available to subscribers to Merrill's Health Tech Weekly. Log in or click here to subscribe.

Personalized Cancer Care Off to Slow Start

by GoozNews ~ 01 Feb 2010 07:45am

With the cost of new cancer drugs soaring to $10,000 a month or more, genomic analyses of cancer tumors hold out the hope that oncologists will be able to identify in advance which patients will benefit from use of pricey new drugs. A new draft report from the Agency for Healthcare Research and Quality suggests that day is still a ways off.

The study looked at whether the presence of specific mutations in people who had breast and colon cancer and chronic myeloid leukemia determined if patients would respond to expensive new drugs commonly used to fight the diseases. Only in colon cancer did the mutation matter and in that case, while it ruled out the effectiveness of drug therapy, the relevant mutation only appears in a small percentage of cases.

In the finding most likely to cause controversy, the AHRQ report found there was "no consistent associations" between breast cancer patients with the relevant CYP2D6 polymorphism and the outcome of tamoxifen therapy, whether as primary treatment or in as post-operative adjuvant therapy.

Regional Variation Revisited: Price Differences Not A Significant Factor

by GoozNews ~ 29 Jan 2010 07:00am

Dartmouth scholars have revisited their analysis of regional variation in health  care spending and found contrary to the assertions of some critics that cost-of-living differentials do not account for much of the difference. However, they confirmed that some big cities with high poverty concentrations that also serve as training grounds for future physicians may have been unfairly lumped in with areas that overuse health care services.

The new study in Health Affairs showed after adjusting for price differences that Miami, Florida and McAllen, Texas still led the pack in terms of how much Medicare spent on each beneficiary. Both areas still spent nearly three times more than the lowest spending regions of the country, which remained Honolulu, Hawaii and LaCrosse, Wisconsin. 

There were a few areas of the country where the adjustments made a big difference, and they were mostly big cities. The Bronx and Manhattan in New York City fell 39 and 33 percent, respectively, from the adjustments. But price was only a minor factor, according to the researchers, who were led by Daniel Gottlieb of the Dartmouth Institute for Health Policy and Clinical Practice.

Much of the reason why the New York metropolitan area is so costly is not because of the wage index per se (what we usually think of as "cost-of-living" adjustments), but because the CMS pays hospitals in the New York area so much to reimburse them for graduate medical education and caring for disproportionate shares of low-income patients.

Other high-spending areas frequently targeted by critics did not do so well under the adjustments. Los Angeles, for instance, dropped just 14 percent after adjusting for cost-of-living, graduate education and disproportionate share payments for low-income residents.

The Medicare Payment Advisory Commission issued a report late last year that suggested regional variation in use patterns were less than the Dartmouth Atlas of Health scholars had previously estimated. This latest study says regional variation still matter -- a lot. The debate clearly isn't over.

Here's the list of the ten highest and ten lowest spending areas in the country both before and after adjustments for price, graduate medical education and disproportionate share payments:

10 high-spending hospital regions:

                            BEFORE        AFTER    % CHG.

FL-Miami               $15,909     $14,966      6%
TX-McAllen              13,633       13,881      -2
NY-Bronx                12,004         8,653      39
NY-Manhattan          11,744         8,861      33
TX-Harlingen            11,489       11,324      1
CA-Los Angeles        10,674         9,325      14
NY-Long Island        10,608         8,740      21
MI-Dearborn            10,460         9,791        7
LA-Monroe               10,226       11,385     -10
MI-Detroit                 9,954         9,541       4

10 low-spending hospital regions:
ND-Minot                   6,033         6,711     -10
VA-Lynchburg             6,022         6,524      -8
CO-Grand Junction      5,983         6,075      -2
OR-Eugene                5,968         5,798       3
IA-Iowa City               5,902         6,254      -6
SD-Rapid City             5,854         6,176      -5
OR-Salem                  5,810         5,642       3
IA-Dubuque               5,799         6,219      -7
WI-La Crosse             5,715         5,757      -1
HI-Honolulu               5,293         5,212       2

5 hospital regions with biggest drop due to price and other factors:

NY-Bronx                   12,004         8,653     39
NY-Manhattan            11,744         8,861     33
CA-Alameda County     9,251         7,094     30
CA-San Francisco         8,140          6,278    30
CA-San Mateo County  7,878          6,104     29

Study: Raising Co-Pays Raises Hospital Costs

by GoozNews ~ 28 Jan 2010 01:51pm

A new study in the latest New England Journal of Medicine shows that raising co-pays in Medicare led to higher hospitalization rates and higher health care costs. The 866,000-person study compared Medicare beneficiaries in plans who had their co-pays raised to people who did not. For every 100 enrollees, the first group experienced 19.8 fewer physician visits, but 13.4 more days in the hospital. "The effects of increases in copayments for ambulatory care were magnified among enrollees living in areas of lower income and education and among enrollees who had hypertension, diabetes, or a history of myocardial infarction," the authors noted.

This is one more piece of evidence showing that forcing medical consumers to have "more skin in the game" -- like taxing high-cost insurance plans -- will backfire when it comes to reducing long-term health care costs.

 

Syndicate content Syndicate content